Pilot study of etretinate in psoriatic arthritis

A. V. Klinkhoff, Elie Gertner, A. Chalmers, D. D. Gladman, W. D. Steward, G. D. Schachter, R. K. Schachter

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


A 2-center pilot study compared clinical and laboratory outcomes in 40 patients with psoriatic arthritis before and after treatment for 8 to 24 weeks with the vitamin A derivative, etretinate. The number of tender joints fell from 22.0 ± 8.75 before treatment to 11.44 ± 8.50 after treatment (p = .000). The duration of morning stiffness was 101.95 ± 62.45 min before therapy and 44.53 ± 82.10 min after treatment (p = 0.0004). Similar highly clinically and statistically significant improvement was seen in all clinical outcome measures and in the erythrocyte sedimentation rate. Primarily mucocutaneous side effects were seen in 39/40 patients and resulted in treatment termination before 24 weeks in 9 patients.

Original languageEnglish (US)
Pages (from-to)789-791
Number of pages3
JournalJournal of Rheumatology
Issue number6
StatePublished - Jan 1 1989


Dive into the research topics of 'Pilot study of etretinate in psoriatic arthritis'. Together they form a unique fingerprint.

Cite this